Prognostic value of serum amyloid A in patients with COVID-19
- PDF / 678,146 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 12 Downloads / 154 Views
ORIGINAL PAPER
Prognostic value of serum amyloid A in patients with COVID‑19 Li Cheng1 · Jian‑Zhong Yang2 · Wen‑Hui Bai3 · Zhuan‑Yun Li2 · Li‑Fang Sun1 · Juan‑Juan Yan1 · Chen‑Liang Zhou1 · Bao‑Peng Tang4 Received: 9 April 2020 / Accepted: 19 June 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Objective To investigate the prognostic value of serum amyloid A (SAA) in the patients with Corona Virus Disease 2019 (COVID-19). Methods The medical data of 89 COVID-19 patients admitted to Renmin Hospital of Wuhan University from January 3, 2020 to February 26, 2020 were collected. Eighty-nine cases were divided into survival group (53 cases) and non-survival group (36 cases) according to the results of 28-day follow-up. The SAA levels of all patients were recorded and compared on 1 day after admission (before treatment) and 3 days, 5 days, and 7 days after treatment. The ROC curve was drawn to analyze the prognosis of patients with COVID-19 by SAA. Results The difference of comparison of SAA between survival group and non-survival group before treatment was not statistically significant, Z1 = − 1.426, P = 0.154. The Z1 values (Z1 is the Z value of the rank sum test) of the two groups of patients at 3 days, 5 days, and 7 days after treatment were − 5.569, − 6.967, and − 7.542, respectively. The P values were all less than 0.001, and the difference was statistically significant. The ROC curve results showed that SAA has higher sensitivity to the prognostic value of 1 day (before treatment), 3 days, 5 days, and 7 days after treatment, with values of 0.806, 0.972, 0.861, and 0.961, respectively. Compared with SAA on the 7th day and C-reactive protein, leukocyte count, neutrophil count, lymphocyte count, and hemoglobin on the 7th day, the sensitivities were: 96.1%, 83.3%, 88.3%, 83.3%, 67.9%, and 83.0%, respectively, of which SAA has the highest sensitivity. Conclusion SAA can be used as a predictor of the prognosis in patients with COVID-19. Keywords COVID-19 · Serum amyloid A · Prognosis
Li Cheng, Jian-Zhong Yang, and Wen-Hui Bai have contributed equally to this work. * Chen‑Liang Zhou [email protected]
Juan‑Juan Yan [email protected]
* Bao‑Peng Tang [email protected]
1
Li Cheng [email protected]
Intensive Care Unit, Renmin Hospital of Wuhan University, Eastern Campus, Wuhan, China
2
Jian‑Zhong Yang [email protected]
Department of Emergency, Xinjiang Medical University Affiliated First Hospital, Xinjiang, China
3
Wen‑Hui Bai [email protected]
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Eastern Campus, Wuhan, China
4
Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Xinjiang, China
Zhuan‑Yun Li [email protected] Li‑Fang Sun [email protected]
13
Vol.:(0123456789)
L. Cheng et al.
Introduction
Research method
Since December 2019, cases of pneumonia of unknown origin have been reported in Wuhan, Hubei Province. On January 7, 2020, the virus was identified as severe acute respiratory syndro
Data Loading...
